EUVIMEDEUVIMED entdecken
Open Access

Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma

Jun Okui, Laura R Prakash, Heather G Lyu, Ryan B Morgan, Jenny J Li, Mariela A Blum-Murphy, Jaffer A Ajani, Wayne L Hofstetter, David C Rice, Paul F Mansfield, Stephen G Swisher, Brian D Badgwell und 1 weitere

JAMA Surgery · 2026

DOI: 10.1001/jamasurg.2026.0861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, 2026. Verfasst von Jun Okui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Adenocarcinoma, Microsatellite Instability, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Comprehensive clinical data stratified by microsatellite instability (MSI) status in gastroesophageal adenocarcinoma (GEA) are limited.

Objective

To characterize treatment pathways and clinical outcomes following immune checkpoint inhibitor (ICI) therapy in patients with deficient mismatch repair (dMMR) or MSI-high (MSI-H) GEA. Design, Setting, and Participants This retrospective cohort study was conducted from June 2020 to August 2025 at a single tertiary cancer center in Texas. Of 3316 patients diagnosed with GEA, 1638 who underwent MSI testing were included. Exposures ICI-based therapy with nivolumab plus ipilimumab or with pembrolizumab. Main Outcomes and Measures Incidence of dMMR, overall survival, best objective response, clinical or pathological complete response (cCR/pCR), and clinicopathological factors associated with ICI response.

Results

Among the 1638 patients included, the mean (SD) age was 62.5 (12.8) years, and 1204 (73.5%) were male. There were 83 individuals (5.1%) with dMMR tumors. The 3-year overall survival rate for patients with dMMR was 84.7% with and 68.5% without curative-intent surgery vs 72.3% with and 32.3% without curative-intent surgery for patients with proficient mismatch repair. Among the 83 patients with dMMR, 34 had metastatic and 49 had locoregional disease; 30 and 25 patients in each group received ICI-based therapy, respectively, with 16 of 26 evaluable patients (61.5%) achieving best objective response and 12 of 23 (52.2%) achieving pCR/cCR, respectively (both considered ICI responsive). Among the 25 locoregional cases treated with ICI, 10 proceeded to surgery, with all achieving residual tumor (R0) resection and 3 (30%) demonstrating pCR. Of the remaining patients, 9 achieved cCR and were transitioned to active surveillance. For patients who achieved cCR or pCR, response was reached after 2 to 4 cycles of nivolumab plus ipilimumab or 6 to 12 cycles of pembrolizumab, and none experienced recurrence or death (median [IQR] follow-up after achieving cCR or pCR, 26.0 [16.3-40.0] months). Individuals who were ICI responsive and nonresponsive did not significantly differ in human epidermal growth factor receptor 2 (ERBB2; formerly HER2 or HER2/neu) status, combined positive score, or claudin-18, isoform 2 (CLDN18.2), expression, whereas Lynch syndrome was more common in responders. Conclusions and Relevance In this single-center cohort of dMMR GEA, ICI-based therapy demonstrated high response rates in both metastatic and locoregional settings. The durable responses in locoregional disease suggest the potential to consider nonoperative management in selected individuals. Further research is needed to improve prediction of ICI response and refine treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaMicrosatellite InstabilityEsophageal NeoplasmsStomach NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansMaleRetrospective StudiesFemaleMiddle AgedAntibodies, Monoclonal, HumanizedPathologic Complete ResponseIpilimumabAgedNivolumabDNA Mismatch RepairAntineoplastic Combined Chemotherapy ProtocolsSurvival Rate

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorspembrolizumabIpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston.

Zitieren

APA

Okui, J., Prakash, L. R., Lyu, H. G., Morgan, R. B., Li, J. J., Blum-Murphy, M. A., Ajani, J. A., Hofstetter, W. L., Rice, D. C., Mansfield, P. F., Swisher, S. G., Badgwell, B. D., & Ikoma, N. (2026). Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma. JAMA Surgery. https://doi.org/10.1001/jamasurg.2026.0861

Vancouver

Okui J, Prakash LR, Lyu HG, Morgan RB, Li JJ, Blum-Murphy MA, et al. Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma. JAMA Surgery. 2026. doi:10.1001/jamasurg.2026.0861

BibTeX
@article{Okui2026,
  author = {Okui, Jun and Prakash, Laura R and Lyu, Heather G and Morgan, Ryan B and Li, Jenny J and Blum-Murphy, Mariela A and Ajani, Jaffer A and Hofstetter, Wayne L and Rice, David C and Mansfield, Paul F and Swisher, Stephen G and Badgwell, Brian D and Ikoma, Naruhiko},
  title = {Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma},
  journal = {JAMA Surgery},
  year = {2026},
  doi = {10.1001/jamasurg.2026.0861}
}
Kostenlos starten →